Robert M Prins

Title(s)Professor, Neurosurgery
SchoolMedicine
ORCID ORCID Icon0000-0002-6282-6583 Additional info
vCardDownload vCard
    Other Positions
    Title(s)Professor, Molecular and Medical Pharmacology


    Collapse Biography 
    Collapse Education and Training
    UCLA, Los AngelesB.S.06/1992Kinesiology
    UCLA, Los AngelesM.S.06/1996Physiological Science
    Medical College of Virginia/Virginia Commonwealth University, RichmondPh.D.06/2001Anatomy & Immunology
    Cedars-Sinai Neurosurgical Institute, Los AngelesFellowship2002Tumor Immunology
    David Geffon School of Medicine at UCLA , Los AngelesFellowship2003Brain Tumor Immunotherapy

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Neoadjuvant checkpoint blockade for recurrent glioblastoma
    NIH R01CA267726Aug 1, 2022 - Apr 30, 2027
    Role: Principal Investigator
    Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
    NIH R01CA222695Apr 1, 2019 - Mar 31, 2024
    Role: Principal Investigator
    UCLA SPORE in Brain Cancer
    NIH P50CA211015Aug 11, 2017 - Jul 31, 2022
    Role: Co-Investigator
    Immunotherapeutic targeting of the Glioblastoma Mutanome
    NIH R21CA186004Jan 16, 2015 - Dec 31, 2017
    Role: Principal Investigator
    Optimizing Induction Conditions for Immunotherapeutic CTL
    NIH R01CA154256Jul 13, 2010 - May 31, 2016
    Role: Principal Investigator
    CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    NIH R01CA123396Apr 1, 2007 - Jul 31, 2012
    Role: Principal Investigator
    Immune targeting of melanoma-associated antigens in glioma
    NIH K01CA111402Jul 1, 2006 - Jun 30, 2012
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1850-1866. Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, Guemes M, Galic Z, Phyu S, Okada H, Grausam KB, Breunig JJ, Brown CE, Nathanson DA, Prins RM, Chen YY. PMID: 38982561; PMCID: PMC11449012.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    2. Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma. Cancer Res Commun. 2024 Jul 01; 4(7):1834-1849. Lai TJ, Sun L, Li K, Prins TJ, Treger J, Li T, Sun MZ, Nathanson DA, Liau LM, Lai A, Prins RM, Everson RG. PMID: 38856710; PMCID: PMC11275559.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nat Commun. 2024 Jun 05; 15(1):4800. Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. PMID: 38839763; PMCID: PMC11153605.
      View in: PubMed   Mentions:    Fields:    
    4. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nat Commun. 2024 May 08; 15(1):3882. Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. PMID: 38719809; PMCID: PMC11078958.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    5. Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI. Eur Radiol. 2024 May; 34(5):3087-3101. Sanvito F, Raymond C, Cho NS, Yao J, Hagiwara A, Orpilla J, Liau LM, Everson RG, Nghiemphu PL, Lai A, Prins R, Salamon N, Cloughesy TF, Ellingson BM. PMID: 37882836; PMCID: PMC11045669.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    6. Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients. Res Sq. 2023 Sep 12. Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. PMID: 37790490; PMCID: PMC10543402.
      View in: PubMed   Mentions:
    7. Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors. J Clin Invest. 2023 09 01; 133(17). Sun L, Kienzler JC, Reynoso JG, Lee A, Shiuan E, Li S, Kim J, Ding L, Monteleone AJ, Owens GC, Phillips JJ, Everson RG, Nathanson D, Cloughesy TF, Li G, Liau LM, Hugo W, Kim W, Prins RM. PMID: 37655659; PMCID: PMC10471177.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    8. Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival. Acta Neuropathol. 2023 10; 146(4):647-649. Wirsching HG, Felsberg J, Prummer M, Moisoiu V, Lourman R, Hertler C, Antonios M, Cimino PJ, Roth P, Gorlia T, Prins RM, Cloughesy T, Wen PY, Holland EC, Reifenberger G, Weller M. PMID: 37573572; PMCID: PMC10499942.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors. Front Immunol. 2023; 14:1176994. Ding L, Sun L, Bu MT, Zhang Y, Scott LN, Prins RM, Su MA, Lechner MG, Hugo W. PMID: 37435085; PMCID: PMC10330698.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    10. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. Proc Natl Acad Sci U S A. 2023 05 23; 120(21):e2221116120. Pan Y, Phillips JW, Zhang BD, Noguchi M, Kutschera E, McLaughlin J, Nesterenko PA, Mao Z, Bangayan NJ, Wang R, Tran W, Yang HT, Wang Y, Xu Y, Obusan MB, Cheng D, Lee AH, Kadash-Edmondson KE, Champhekar A, Puig-Saus C, Ribas A, Prins RM, Seet CS, Crooks GM, Witte ON, Xing Y. PMID: 37192158; PMCID: PMC10214192.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    11. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduct Target Ther. 2023 04 17; 8(1):155. Hu J, Tan P, Ishihara M, Bayley NA, Schokrpur S, Reynoso JG, Zhang Y, Lim RJ, Dumitras C, Yang L, Dubinett SM, Jat PS, Van Snick J, Huang J, Chin AI, Prins RM, Graeber TG, Xu H, Wu L. PMID: 37069149; PMCID: PMC10110583.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    12. Commentary on "Dysfunctional dendritic cells limit antigen-specific T cell response in glioma". Neuro Oncol. 2023 02 14; 25(2):277-278. Prins RM, Everson RG. PMID: 36445342; PMCID: PMC9925671.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    13. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell. 2023 02 13; 41(2):235-251.e9. Kilian M, Sheinin R, Tan CL, Friedrich M, Krämer C, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins RM, Etminan N, von Deimling A, Wick W, Madi A, Bunse L, Platten M. PMID: 36638785.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    14. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023 01 01; 9(1):112-121. Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudhary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML. PMID: 36394838; PMCID: PMC9673026.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCellsPHPublic Health
    15. Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. NMR Biomed. 2023 06; 36(6):e4785. Cho NS, Hagiwara A, Yao J, Nathanson DA, Prins RM, Wang C, Raymond C, Desousa BR, Divakaruni A, Morrow DH, Nghiemphu PL, Lai A, Liau LM, Everson RG, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. PMID: 35704275.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    16. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro Oncol. 2022 06 01; 24(6):1020-1028. Hagiwara A, Oughourlian TC, Cho NS, Schlossman J, Wang C, Yao J, Raymond C, Everson R, Patel K, Mareninov S, Rodriguez FJ, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Prins RM, Cloughesy TF, Ellingson BM. PMID: 34865129; PMCID: PMC9159421.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    17. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022 01; 3(1):11-24. Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF. PMID: 35121998.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    18. Is there a role for neoadjuvant anti-PD-1 therapies in glioma? Curr Opin Neurol. 2021 12 01; 34(6):834-839. Sun L, Lai TJ, Prins RM. PMID: 34608074; PMCID: PMC8595846.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021 11 26; 12(1):6938. Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, Kienzler JC, Everson RG, Nathanson DA, Bensinger SJ, Liau LM, Cloughesy T, Hugo W, Prins RM. PMID: 34836966; PMCID: PMC8626557.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    20. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nat Commun. 2021 06 29; 12(1):4031. Lu Y, Ng AHC, Chow FE, Everson RG, Helmink BA, Tetzlaff MT, Thakur R, Wargo JA, Cloughesy TF, Prins RM, Heath JR. PMID: 34188042; PMCID: PMC8241935.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    21. The immune landscape of common CNS malignancies: implications for immunotherapy. Nat Rev Clin Oncol. 2021 11; 18(11):729-744. Ott M, Prins RM, Heimberger AB. PMID: 34117475; PMCID: PMC11090136.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    22. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375. Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown CE, Chen Y, Fecci PE, Reardon DA, Dunn GP, Liau LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins RM, Platten M, Okada H. PMID: 33367885; PMCID: PMC7992879.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    23. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020 10 14; 22(10):1425-1438. Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. PMID: 32615600; PMCID: PMC7686464.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    24. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245. Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, Mochizuki AY, Prins RM, Kumthekar P, Raizer JJ, Dixit K, Lukas RV, Horbinski C, Wei M, Zhou C, Pawelec G, Campisi J, Grohmann U, Prendergast GC, Munn DH, Wainwright DA. PMID: 32546647; PMCID: PMC7541490.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimals
    25. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro Oncol. 2019 09 06; 21(9):1184-1196. Yao J, Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. PMID: 31066901; PMCID: PMC7594567.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    26. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. J Neurooncol. 2019 May; 142(3):423-434. Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, Prins R, Nghiemphu PL, Yong W, Cloughesy T, Lai A. PMID: 30838489; PMCID: PMC6516751.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    27. Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Sci Rep. 2019 02 26; 9(1):2846. Chakhoyan A, Yao J, Yao J, Leu K, Pope WB, Salamon N, Yong W, Lai A, Nghiemphu PL, Everson RG, Prins RM, Liau LM, Nathanson DA, Cloughesy TF, Ellingson BM. PMID: 30808879; PMCID: PMC6391482.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    28. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. PMID: 30742122; PMCID: PMC6408961.
      View in: PubMed   Mentions: 667     Fields:    Translation:HumansCells
    29. Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients. Front Immunol. 2019; 10:121. Owens GC, Garcia AJ, Mochizuki AY, Chang JW, Reyes SD, Salamon N, Prins RM, Mathern GW, Fallah A. PMID: 30761153; PMCID: PMC6362260.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    30. Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clin Cancer Res. 2019 03 15; 25(6):1913-1922. Davidson TB, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki A, Antonios J, Garcia A, Kotecha N, Bayless N, Nathanson D, Wang A, Everson R, Yong WH, Cloughesy TF, Liau LM, Herold-Mende C, Prins RM. PMID: 30498094; PMCID: PMC6420851.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    31. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res. 2018 08 15; 24(16):3845-3856. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. PMID: 30018119; PMCID: PMC6449174.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    32. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 06 29; 16(1):179. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29958537; PMCID: PMC6026340.
      View in: PubMed   Mentions: 10     Fields:    
    33. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 05 29; 16(1):142. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29843811; PMCID: PMC5975654.
      View in: PubMed   Mentions: 275     Fields:    Translation:HumansCellsCTClinical Trials
    34. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab. 2018; 6:4. Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI. PMID: 29692895; PMCID: PMC5905129.
      View in: PubMed   Mentions: 35  
    35. Precision Medicine in Pediatric Neurooncology: A Review. ACS Chem Neurosci. 2018 01 17; 9(1):11-28. Mochizuki AY, Frost IM, Mastrodimos MB, Plant AS, Wang AC, Moore TB, Prins RM, Weiss PS, Jonas SJ. PMID: 29199818; PMCID: PMC6656379.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    36. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. Brain Tumor Pathol. 2018 Jan; 35(1):1-9. Chung LK, Pelargos PE, Chan AM, Demos JV, Lagman C, Sheppard JP, Nguyen T, Chang YL, Hojat SA, Prins RM, Liau LM, Nghiemphu L, Lai A, Cloughesy TF, Yong WH, Gordon LK, Wadehra M, Yang I. PMID: 28887715; PMCID: PMC6118858.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    37. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10220-10225. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. PMID: 28874539; PMCID: PMC5617282.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    38. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. J Neurooncol. 2017 Aug; 134(1):29-40. Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios JP, Kasahara N, Yang I, Prins RM, Braun J, Gordon LK, Wadehra M. PMID: 28597184; PMCID: PMC5695892.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    39. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 06 01; 19(6):796-807. Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PMID: 28115578; PMCID: PMC5464463.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansAnimalsCells
    40. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016 Jul 07; 1(10). Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PMID: 27453950; PMCID: PMC4951098.
      View in: PubMed   Mentions: 87     Fields:    
    41. TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunol Res. 2016 05; 4(5):412-418. Hsu M, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, Du L, Emerson R, Yusko E, Sanders C, Robins HS, Yong WH, Davidson TB, Li G, Liau LM, Prins RM. PMID: 26968205; PMCID: PMC4873445.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    42. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol. 2016 Mar; 18(3):368-78. Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, Liau LM, Prins RM. PMID: 26330563; PMCID: PMC4767237.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    43. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab. 2015 Sep 01; 22(3):508-15. Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, Faull KF, Jiang M, Clarke SG, Cloughesy TF, Graeber TG, Braas D, Christofk HR, Jung ME, Reue K, Huang J. PMID: 26190651; PMCID: PMC4663076.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansAnimalsCells
    44. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro Oncol. 2015 Nov; 17(11):1514-24. Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. PMID: 26113557; PMCID: PMC4648305.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimals
    45. Radial mobility and cytotoxic function of retroviral replicating vector transduced, non-adherent alloresponsive T lymphocytes. J Vis Exp. 2015 Feb 11; (96). Erickson KL, Hickey MJ, Kato Y, Malone CC, Owens GC, Prins RM, Liau LM, Kasahara N, Kruse CA. PMID: 25741775; PMCID: PMC4354631.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    46. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer. 2014; 2(1):46. Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR. PMID: 25598973; PMCID: PMC4296547.
      View in: PubMed   Mentions: 39     Fields:    
    47. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clin Cancer Res. 2014 Nov 15; 20(22):5808-22. Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, Cloughesy TF, Lai A. PMID: 25224277; PMCID: PMC4233178.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    48. Dominant B-cell epitopes from cancer/stem cell antigen SOX2 recognized by serum samples from cancer patients. Am J Clin Exp Immunol. 2014; 3(2):84-90. Shih J, Rahman M, Luong QT, Lomeli SH, Riss J, Prins RM, Gure AO, Zeng G. PMID: 25143868; PMCID: PMC4138131.
      View in: PubMed   Mentions: 2  
    49. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer. 2014; 2:10. Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM. PMID: 24883189; PMCID: PMC4039989.
      View in: PubMed   Mentions: 18     Fields:    
    50. The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. J Immunother Cancer. 2014; 2:8. Lisiero DN, Soto H, Everson RG, Liau LM, Prins RM. PMID: 25054063; PMCID: PMC4105687.
      View in: PubMed   Mentions: 27     Fields:    
    51. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res. 2013 May; 33(5):2047-56. Lasky JL, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB. PMID: 23645755; PMCID: PMC4018463.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    52. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 2013 May 01; 73(9):2850-62. Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN, Komisopoulou E, Henkin AH, Soto H, Chamberlain BT, Vergnes L, Jung ME, Torres JZ, Liau LM, Christofk HR, Prins RM, Mischel PS, Reue K, Graeber TG, Bensinger SJ. PMID: 23440422; PMCID: PMC3919498.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansAnimalsCells
    53. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013 Feb; 36(2):152-7. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. PMID: 23377664; PMCID: PMC3568250.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    54. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol. 2012 Dec; 14(12):1465-72. Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB. PMID: 23090985; PMCID: PMC3499014.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    55. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst. 2012 Oct 03; 104(19):1458-69. Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A. PMID: 22945948; PMCID: PMC3529615.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    56. Endogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: implications for future targeted therapies. Neurosurg Clin N Am. 2012 Jul; 23(3):451-8. Yang J, Nagasawa DT, Spasic M, Amolis M, Choy W, Garcia HM, Prins RM, Liau LM, Yang I. PMID: 22748657.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    57. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One. 2012; 7(4):e32614. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM, Prins RM. PMID: 22485134; PMCID: PMC3317661.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCellsPHPublic Health
    58. Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas. Am J Transl Res. 2012; 4(1):114-26. Hickey MJ, Malone CC, Erickson KE, Gomez GG, Young EL, Liau LM, Prins RM, Kruse CA. PMID: 22347526; PMCID: PMC3276381.
      View in: PubMed   Mentions: 9  
    59. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med. 2011 Nov 07; 9:192. Konkankit VV, Kim W, Koya RC, Eskin A, Dam MA, Nelson S, Ribas A, Liau LM, Prins RM. PMID: 22060015; PMCID: PMC3229551.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    60. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012 Mar; 107(1):197-205. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. PMID: 22015945; PMCID: PMC3650613.
      View in: PubMed   Mentions: 150     Fields:    Translation:Humans
    61. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct; 1(5):442-56. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS. PMID: 22059152; PMCID: PMC3207317.
      View in: PubMed   Mentions: 231     Fields:    Translation:HumansAnimalsCells
    62. Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model. J Immunol. 2011 May 01; 186(9):5068-77. Lisiero DN, Soto H, Liau LM, Prins RM. PMID: 21430221; PMCID: PMC3532507.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    63. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011 Mar 15; 17(6):1603-15. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. PMID: 21135147; PMCID: PMC3071163.
      View in: PubMed   Mentions: 229     Fields:    Translation:HumansCellsCTClinical Trials
    64. Cellular and vaccine therapeutic approaches for gliomas. J Transl Med. 2010 Oct 14; 8:100. Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, Kruse CA. PMID: 20946667; PMCID: PMC2964608.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    65. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010 Jun 17; 465(7300):966. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. PMID: 20559394; PMCID: PMC3766976.
      View in: PubMed   Mentions: 217     Fields:    Translation:Humans
    66. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009 Dec 15; 2(101):ra82. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. PMID: 20009104; PMCID: PMC2978002.
      View in: PubMed   Mentions: 197     Fields:    Translation:HumansCells
    67. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009 Dec 10; 462(7274):739-44. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. PMID: 19935646; PMCID: PMC2818760.
      View in: PubMed   Mentions: 1860     Fields:    Translation:HumansCells
    68. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009 Nov 15; 69(22):8693-9. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S, Garban HJ, Craft N, Economou JS, Marincola FM, Wang E, Ribas A. PMID: 19861533; PMCID: PMC2779578.
      View in: PubMed   Mentions: 86     Fields:    Translation:AnimalsCells
    69. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):12932-7. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. PMID: 19625624; PMCID: PMC2714280.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansAnimalsCells
    70. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol. 2009 Feb; 21(2):155-65. Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, Phelps ME, Witte ON. PMID: 19106231; PMCID: PMC2638874.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    71. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother. 2009 May; 58(5):699-708. Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A. PMID: 18807035; PMCID: PMC11030969.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    72. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008 Jul 31; 359(5):539-41. Prins RM, Cloughesy TF, Liau LM. PMID: 18669440; PMCID: PMC2775501.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCellsCTClinical Trials
    73. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother. 2008 Sep; 57(9):1279-89. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, Yang MY, Lin MS, Shelly S, Witte ON, Ribas A, Liau LM. PMID: 18253732; PMCID: PMC2614264.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    74. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol Ther. 2007 Jul; 15(7):1390-9. Kimura T, Koya RC, Anselmi L, Sternini C, Wang HJ, Comin-Anduix B, Prins RM, Faure-Kumar E, Rozengurt N, Cui Y, Kasahara N, Stripecke R. PMID: 17505480.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCellsPHPublic Health
    75. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol. 2006 Dec 15; 177(12):8448-55. Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. PMID: 17142742.
      View in: PubMed   Mentions: 31     Fields:    Translation:AnimalsCells
    76. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. Expert Rev Neurother. 2006 Oct; 6(10):1481-94. Yang MY, Zetler PM, Prins RM, Khan-Farooqi H, Liau LM. PMID: 17078788.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    77. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden. Neurosurgery. 2006 Jan; 58(1):169-78; discussion 169-78. Prins RM, Bruhn KW, Craft N, Lin JW, Kim CH, Odesa SK, Miller JF, Liau LM. PMID: 16385341.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCellsPHPublic Health
    78. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006 Jan 01; 176(1):157-64. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. PMID: 16365406.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimalsCells
    79. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. Neurol Res. 2005 Oct; 27(7):692-702. Khan-Farooqi HR, Prins RM, Liau LM. PMID: 16197806.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    80. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol. 2005 Aug 01; 175(3):1983-90. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM, Miller JF. PMID: 16034143.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    81. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 01; 11(15):5515-25. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. PMID: 16061868.
      View in: PubMed   Mentions: 247     Fields:    Translation:HumansCellsCTClinical Trials
    82. Bioluminescent imaging of melanoma in live mice. J Invest Dermatol. 2005 Jul; 125(1):159-165. Craft N, Bruhn KW, Nguyen BD, Prins R, Liau LM, Collisson EA, De A, Kolodney MS, Gambhir SS, Miller JF. PMID: 15982316; PMCID: PMC4141554.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    83. Cellular immunity and immunotherapy of brain tumors. Front Biosci. 2004 Sep 01; 9:3124-36. Prins RM, Liau LM. PMID: 15353342.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    84. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity. J Immunol. 2004 Feb 01; 172(3):1602-11. Prins RM, Incardona F, Lau R, Lee P, Claus S, Zhang W, Black KL, Wheeler CJ. PMID: 14734741.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    85. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg. 2004 Feb; 100(2):310-9. Yang I, Kremen TJ, Giovannone AJ, Paik E, Odesa SK, Prins RM, Liau LM. PMID: 15086239.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    86. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 2003 Dec 01; 63(23):8487-91. Prins RM, Odesa SK, Liau LM. PMID: 14679014.
      View in: PubMed   Mentions: 55     Fields:    Translation:AnimalsCells
    87. Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression. J Neurooncol. 2003 Aug-Sep; 64(1-2):45-54. Prins RM, Graf MR, Merchant RE, Black KL, Wheeler CJ. PMID: 12952285.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    88. Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery. J Neuroimmunol. 2003 Jul; 140(1-2):49-60. Graf MR, Prins RM, Poulsen GA, Merchant RE. PMID: 12864971.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    89. Immunology and immunotherapy in neurosurgical disease. Neurosurgery. 2003 Jul; 53(1):144-52; discussion 152-3. Prins RM, Liau LM. PMID: 12823883.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    90. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol Immunother. 2002 Jun; 51(4):190-9. Prins RM, Scott GP, Merchant RE, Graf MR. PMID: 12012106; PMCID: PMC11034233.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCellsPHPublic Health
    91. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination. Cancer Immunol Immunother. 2002 Jun; 51(4):179-89. Graf MR, Prins RM, Hawkins WT, Merchant RE. PMID: 12012105; PMCID: PMC11032860.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCellsPHPublic Health
    Robert's Networks
    Concepts (369)
    Derived automatically from this person's publications.
    _
    Co-Authors (79)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _